Clinical Trials

NCT03677739 | ACTIVE_NOT_RECRUITING | NA
1160 participants

Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-22
Start Date:
2019-06-03
Completion:
2025-12-31
Conditions
  • Clinical Stage 0 Cutaneous Melanoma AJCC v8
  • Clinical Stage I Cutaneous Melanoma AJCC v8
  • Clinical Stage IA Cutaneous Melanoma AJCC v8
  • Clinical Stage IB Cutaneous Melanoma AJCC v8
  • Clinical Stage II Cutaneous Melanoma AJCC v8
  • Clinical Stage IIA Cutaneous Melanoma AJCC v8
  • Clinical Stage IIB Cutaneous Melanoma AJCC v8
  • Clinical Stage IIC Cutaneous Melanoma AJCC v8
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • First Degree Relative
  • Pathologic Stage 0 Cutaneous Melanoma AJCC v8
  • Pathologic Stage I Cutaneous Melanoma AJCC v8
  • Pathologic Stage IA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IB Cutaneous Melanoma AJCC v8
  • Pathologic Stage II Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIB Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIC Cutaneous Melanoma AJCC v8
  • Pathologic Stage III Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Interventions
  • OTHER
No Results Yet
NCT03589729 | RECRUITING | PHASE2
100 participants

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-22
Start Date:
2018-09-19
Completion:
2027-12-31
Conditions
  • Acute Myeloid Leukemia
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Blasts 10 Percent or More of Bone Marrow Nucleated Cells
  • High Risk Myelodysplastic Syndrome
  • Myeloid Sarcoma
  • Myeloproliferative Neoplasm
  • Philadelphia Chromosome Positive
Interventions
  • DRUG
No Results Yet
NCT03449108 | ACTIVE_NOT_RECRUITING | PHASE2
30 participants

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-22
Start Date:
2018-04-27
Completion:
2027-04-30
Conditions
  • Bone Sarcoma
  • Dedifferentiated Chondrosarcoma
  • Giant Cell Tumor of Bone
  • Malignancy in Giant Cell Tumor of Bone
  • Malignant Solid Neoplasm
  • Ovarian Carcinosarcoma
  • Platinum-Resistant Ovarian Carcinoma
  • Poorly Differentiated Thyroid Gland Carcinoma
  • Recurrent Osteosarcoma
  • Recurrent Ovarian Carcinoma
  • Refractory Osteosarcoma
  • Soft Tissue Sarcoma
  • Thyroid Gland Anaplastic Carcinoma
  • Thyroid Gland Squamous Cell Carcinoma
  • Undifferentiated High Grade Pleomorphic Sarcoma of Bone
  • Triple Negative Breast Cancer
Interventions
  • BIOLOGICAL
  • DRUG
  • OTHER
No Results Yet
NCT03394365 | RECRUITING | PHASE3
115 participants

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-22
Start Date:
2017-12-29
Completion:
2030-05-31
Conditions
  • Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
  • Solid Organ Transplant Complications
  • Lymphoproliferative Disorders
  • Allogeneic Hematopoietic Cell Transplant
  • Stem Cell Transplant Complications
Interventions
  • BIOLOGICAL
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page